First Human Dosing of Gerilimzumab

RuiYi initiates clinical trial for autoimmune disorders drug

25-Sep-2015 - arGEN-X reports that its partner RuiYi, Inc., has announced the first human dosing of Gerilimzumab, a novel monoclonal antibody neutralizing the IL-6 cytokine, for the treatment of autoimmune disorders including rheumatoid arthritis. arGEN-X licensed the worldwide rights to develop and ...

arGEN-X and University of Bern enter into license agreement to develop ARGX-110-based combination therapies for treatment-resistant cancers

03-Aug-2015 - arGEN-X N.V. and the Clinical Research Department of the University of Bern announce an exclusive license agreement enabling arGEN-X to develop and commercialize ARGX-110-based therapies to overcome treatment resistance mechanisms in hematologic tumors. The license agreement has arisen from a ...

arGEN-X and LEO Pharma Enter into Alliance to Develop Antibody-based Treatments for Skin Conditions

26-May-2015 - arGEN-X N.V. and LEO Pharma A/S announced an alliance in which they will collaborate to develop antibody-based solutions for the treatment of chronic inflammation underlying many skin conditions.Under the terms of the agreement, LEO Pharma receives exclusive access to an existing arGEN-X ...

arGEN-X awarded €1.5 million IWT grant to advance the application of NHance Fc modifications in therapeutic antibodies

20-May-2015 - arGEN-X N.V. announced that it has received a € 1.5 million grant from the Institute for the Promotion of Innovation by Sciences and Technology in Flanders (IWT). This grant will be used to advance and commercialize the application of the NHance® Fc modifications in therapeutic antibodies.“We ...

arGEN-X Submits Investigational New Drug Application to Evaluate ARGX-110 in Waldenström’s Macroglobulinemia

04-Nov-2014 - arGEN-X N.V. announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to initiate a Phase 1b/2 trial of ARGX-110 in patients with relapsed or refractory Waldenström’s macroglobulinemia. ARGX-110 is a novel anti-CD70 antibody ...

arGEN-X announces collaboration with Bayer to discover and develop therapeutic antibody candidates

02-Jun-2014 - arGEN-X announced the initiation of a collaboration with Bayer Pharma AG (Bayer), leveraging arGEN-X’s SIMPLE Antibody™ technology for the discovery and development of therapeutic antibodies. The collaboration centers on a novel approach to addressing complex targets across multiple therapeutic ...

arGEN-X initiates Phase Ib study of ARGX-110 in cancer

08-Jan-2013 - arGEN-X announced the initiation of a Phase Ib first-in-man cancer study with ARGX-110, its first SIMPLE Antibody™ program to enter the clinic in just three years from initiation of discovery. ARGX-110 is a first-in-class CD70-targeting monoclonal antibody that addresses both known mechanisms of ...

arGEN-X appoints Dr. David L. Lacey to its Supervisory Board

29-Oct-2012 - arGEN-X has strengthened its supervisory board with the appointment of Dr. David L. Lacey.Dr. Lacey is a former Senior Vice President and Head of Discovery Research at Amgen with over 30 years of basic and clinical research experience. He played a fundamental role in the discovery of the ...

arGEN-X enters into therapeutic antibody alliance with Shire

02-Mar-2012 - arGEN-X announced that it has entered into an alliance with Shire to create novel therapeutic antibody products against multiple targets submitted by Shire. Using its SIMPLE Antibody™ discovery technology, arGEN-X will isolate and characterize human antibodies against the targets that Shire has ...

arGEN-X advances third therapeutic antibody program into preclinical development

10-Feb-2012 - arGEN-X announced that it has progressed ARGX-111, its third therapeutic candidate, into formal preclinical development.ARGX-111 is a novel, fully human antibody specific for c-Met, a receptor tyrosine kinase involved in cell proliferation, angiogenesis and metastasis. c-Met is widely implicated ...